JP2025134707A5 - - Google Patents
Info
- Publication number
- JP2025134707A5 JP2025134707A5 JP2025085673A JP2025085673A JP2025134707A5 JP 2025134707 A5 JP2025134707 A5 JP 2025134707A5 JP 2025085673 A JP2025085673 A JP 2025085673A JP 2025085673 A JP2025085673 A JP 2025085673A JP 2025134707 A5 JP2025134707 A5 JP 2025134707A5
- Authority
- JP
- Japan
- Prior art keywords
- δ1γδt
- cells
- sequence
- cell
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739822P | 2018-10-01 | 2018-10-01 | |
| US62/739,822 | 2018-10-01 | ||
| PCT/US2019/054132 WO2020072536A1 (en) | 2018-10-01 | 2019-10-01 | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
| JP2021542089A JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Division JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025134707A JP2025134707A (ja) | 2025-09-17 |
| JP2025134707A5 true JP2025134707A5 (cg-RX-API-DMAC10.html) | 2026-04-01 |
Family
ID=68393055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Country Status (11)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| BR112021006182A2 (pt) * | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| BR112022001194A2 (pt) * | 2019-07-24 | 2022-06-07 | Regeneron Pharma | Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113667640B (zh) * | 2021-08-27 | 2022-09-02 | 广州百暨基因科技有限公司 | CAR-γδT细胞的制备方法 |
| AU2022401701A1 (en) * | 2021-12-05 | 2024-06-20 | Adicet Therapeutics, Inc. | Treatment of b cell malignancies |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| WO2025011459A1 (en) * | 2023-07-07 | 2025-01-16 | Nanjing Legend Biotech Co., Ltd. | Proteins and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) * | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| SG188175A1 (en) * | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| PT1809321E (pt) | 2004-10-08 | 2012-05-17 | Us Gov Health & Human Serv | Imunoterapia adotiva com sobrevivência aumentada de linfócitos |
| EP1891113A2 (en) * | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| JP5588865B2 (ja) | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｃｄ２０に対するヒト抗体及びその使用方法 |
| WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2710123B1 (en) | 2011-05-19 | 2017-07-12 | Instituto de Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| EP3919079A1 (en) * | 2012-09-07 | 2021-12-08 | Genentech, Inc. | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| CN104087607B (zh) | 2013-04-01 | 2017-06-20 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| US9907820B2 (en) | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| WO2016034666A1 (en) * | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP6799895B2 (ja) | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| CA3172801A1 (en) * | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| CN107523545A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| CN110035768A (zh) | 2016-07-26 | 2019-07-19 | 泰莎治疗私人有限公司 | 嵌合抗原受体 |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| CA3042613A1 (en) * | 2016-11-11 | 2018-05-17 | Autolus Limited | Chimeric antigen receptor |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| TWI831365B (zh) | 2017-01-10 | 2024-02-01 | 國立大學法人山口大學 | 抗ｇｐｃ３抗體 |
| EP3572427B1 (en) | 2017-01-23 | 2025-06-25 | CRAGE medical Co., Limited | Bcma-targeting antibody and use thereof |
| GB201701332D0 (en) | 2017-01-26 | 2017-03-15 | Tc Biopharm Ltd | Immune cells with modified metabolism and their use thereof |
| MY200528A (en) * | 2017-02-08 | 2023-12-30 | Agency Science Tech & Res | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same |
| GB2562774A (en) | 2017-05-25 | 2018-11-28 | Mcdonald Michael | Genetic construct |
| KR20200021074A (ko) | 2017-06-14 | 2020-02-27 | 아디셋 바이오, 인크. | Hla 제한된 방식으로 hla-a2/tyrd를 결합할 수 있는 항체 및 이의 용도 |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| WO2019210293A1 (en) * | 2018-04-27 | 2019-10-31 | Baylor College Of Medicine | Car t cells with one or more interleukins |
| CN108588023B (zh) | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| WO2020017479A1 (ja) | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| WO2020061048A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
| BR112021006182A2 (pt) * | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
-
2019
- 2019-10-01 BR BR112021006182-7A patent/BR112021006182A2/pt unknown
- 2019-10-01 CN CN201980070384.5A patent/CN113056283A/zh active Pending
- 2019-10-01 WO PCT/US2019/054132 patent/WO2020072536A1/en not_active Ceased
- 2019-10-01 US US17/281,574 patent/US12692319B2/en active Active
- 2019-10-01 SG SG11202103235PA patent/SG11202103235PA/en unknown
- 2019-10-01 MX MX2021003745A patent/MX2021003745A/es unknown
- 2019-10-01 EA EA202190926A patent/EA202190926A1/ru unknown
- 2019-10-01 CA CA3115139A patent/CA3115139A1/en active Pending
- 2019-10-01 JP JP2021542089A patent/JP7687952B2/ja active Active
- 2019-10-01 EP EP19795699.8A patent/EP3860645A1/en active Pending
-
2021
- 2021-03-31 IL IL281922A patent/IL281922A/en unknown
-
2025
- 2025-05-22 JP JP2025085673A patent/JP2025134707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522357A (ja) | クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 | |
| JP4317817B2 (ja) | 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体 | |
| EP1786837B1 (en) | Antibodies to dkk-1 | |
| JP2022065073A (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| JP2023139070A5 (cg-RX-API-DMAC10.html) | ||
| WO2019129053A1 (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2022501074A5 (cg-RX-API-DMAC10.html) | ||
| CN107530419A (zh) | 治疗疾病的组合疗法 | |
| WO2017148424A1 (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| JP2024531409A5 (cg-RX-API-DMAC10.html) | ||
| CN111518211A (zh) | 抗人白介素4受体α单克隆抗体的制药用途 | |
| WO2002034292A1 (fr) | Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active | |
| CN110114371A (zh) | 嵌合抗原受体 | |
| JP2022542559A5 (cg-RX-API-DMAC10.html) | ||
| CN117858906A (zh) | 与cldn18.2和cd3结合的双特异性结合剂 | |
| TWI876192B (zh) | 人類介白素-4受體α抗體 | |
| JP2022513321A5 (cg-RX-API-DMAC10.html) | ||
| CN114786723A (zh) | 序贯抗cd19疗法 | |
| JP2024540275A5 (cg-RX-API-DMAC10.html) | ||
| EP3013858A1 (en) | Il-21 binding proteins and uses thereof | |
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| CN117777290B (zh) | 一种特异性识别cldn18.2的单克隆抗体及其相关产品、方法和用途 | |
| CN119548619A (zh) | 一种双靶点car-t细胞在治疗系统性红斑狼疮及其他b细胞自身免疫病中的用途 | |
| CN111704671B (zh) | Ox40抗体及其在治疗癌症中的应用 | |
| US20230172923A1 (en) | Methods of treating cytokine-related adverse events |